reconstitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-22. Anything still debated is marked as such rather than presented as settled.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
=== Freezers === Freezers act the same way as refrigerators but for extreme temperatures. Its minimum temperature depends on the manufacture. Typically this storage is to store frozen vaccines and maintained temperature between -80 and -15C. Health facilities use purpose-built or pharmaceutical-grade units and vary in size. Dippin' Dots, a manufacturer of frozen desserts, had previously created equipment to preserve its products. This equipment was subsequently utilized by developers of the COVID-19 vaccine for transportation and storage of the vaccine.
== References == Coe, Sophie D. (1994), America's First Cuisines, ISBN 0-292-71159-X Foster, Nelson. Chilies to Chocolate: Food the Americas Gave the World. The Univ. of Arizona Press. Jacobsen, Sven-Erik. "The Worldwide Potential for Quinoa (Chenopodium quinoa Willd.)." Food Reviews International 19.1-2 (2003): 167-177. Jennings, Justin & Guy Duke, ‘Making the typical exceptional: the elevation of Inca cuisine’, in The Oxford Handbook of the Incas. Eds. Sonia Alconini & R. Alan Covey. New York: Oxford University Press, 2018. Popenoe, Hugh, Steven R. King, Jorge Leon, Luis Sumar Kalinowski, and Noel D. Vietmeyer (1989), Lost Crops of the Incas, ISBN 0-309-04264-X
== Abstracting and indexing == The journal is abstracted and indexed by Chemical Abstracts Service, MEDLINE/PubMed, Scopus, and the Science Citation Index Expanded. According to the Journal Citation Reports, the journal has a 2025 impact factor of 2.6.
Alphavirus infection Asymmetric periflexural exanthem of childhood (unilateral laterothoracic exanthem) B virus infection Boston exanthem disease Bovine papular stomatitis Bowenoid papulosis Buffalopox Butcher's wart Chikungunya fever Condylomata acuminata Congenital rubella syndrome Cowpox Cytomegalic inclusion disease Dengue (Break-bone fever) Disseminated herpes zoster Eczema herpeticum (Kaposi's varicelliform eruption) Eczema vaccinatum Epidermodysplasia verruciformis Eruptive pseudoangiomatosis Erythema infectiosum (fifth disease, slapped cheek disease) Exanthem of primary HIV infection (acute retroviral syndrome) Farmyard pox Generalized vaccinia Genital herpes (herpes genitalis, herpes progenitalis) Gianotti–Crosti syndrome (infantile papular acrodermatitis, papular acrodermatitis of childhood, papulovesicular acrolocated syndrome) Giant condyloma acuminatum (Buschke–Löwenstein tumor, giant condyloma of Buschke–Löwenstein tumor) Hand-foot-and-mouth disease Heck's disease (focal epithelial hyperplasia) Hemorrhagic fever with renal syndrome Hepatitis B Hepatitis C Herpangina Herpes gladiatorum (scrum pox) Herpes simplex Herpes zoster oticus (Ramsay–Hunt syndrome) Herpetic keratoconjunctivitis Herpetic sycosis Herpetic whitlow HIV-associated pruritus Human monkeypox Human T-lymphotropic virus 1 infection Human tanapox Immune reconstitution inflammatory syndrome (immune recovery syndrome) Infectious mononucleosis (glandular fever) Inflammatory skin lesions following zoster infection (isotopic response) Intrauterine herpes simplex Kaposi sarcoma Lassa fever Lipschütz ulcer (ulcus vulvae acutum) Measles (rubeola, morbilli) Milker's nodule Modified varicella-like syndrome Molluscum contagiosum Myrmecia Neonatal herpes simplex Ophthalmic zoster Orf (contagious pustular dermatosis, ecthyma contagiosum, infectious labial dermatitis, sheep pox) Orf-induced immunobullous disease Orolabial herpes (herpes labialis) Papular purpuric gloves and socks syndrome Pigmented wart Postherpetic neuralgia (zoster-associated pain) Post-vaccination follicular eruption Progressive vaccinia (vaccinia gangrenosum, vaccinia necrosum) Pseudocowpox Recurrent respiratory papillomatosis (laryngeal papillomatosis) Rift Valley fever Roseola infantum (exanthem subitum, exanthema subitum, sixth disease) Roseola vaccinia Rubella (German measles) Sandfly fever (Pappataci fever, phlebotomus fever) Sealpox Varicella (chickenpox) Variola major (smallpox) Verruca plana (flat wart) Verruca plantaris (plantar wart) Verruca vulgaris (wart) Verrucae palmares et plantares Viral-associated trichodysplasia (ciclosporin-induced folliculodystrophy) Wasting syndrome West Nile virus infection Zoster (herpes zoster, shingles) Zoster sine herpete
Sources: en.wikipedia.org
Southern Association, previously Class A1 (1936–1945) Texas League, previously Class A1 (1936–1942; idle for three seasons during World War II) The Texas League remained in Double-A for the next 75 years. During this time, there were limited changes to leagues at the Double-A level:
Apoptosis & Caspase 3 – PMAP The Proteolysis Map-animation Cytochrome+c at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P99999 (Cytochrome c) at the PDBe-KB.
=== Gradual dissolution === In March 2002, the governments of Montenegro and Serbia, along with the Federal Republic of Yugoslavia (FRY), signed the Accord on Principles in Relations between Serbia and Montenegro (commonly known as the Belgrade Agreement), which outlined the restructuring of their mutual relations. This agreement led to the adoption of the Constitutional Charter of Serbia and Montenegro on 4 February 2003, officially transforming the FRY into the State Union of Serbia and Montenegro and formally retiring the name "Yugoslavia" after 74 years. The Constitutional Charter included a provision allowing either republic to hold a referendum on independence after a three-year transition period. On 21 May 2006, Montenegro held such a referendum. The final results showed that 55.5% of voters supported independence, narrowly surpassing the 55% threshold set by the European Union for the referendum's validity. Voter turnout was 86.5%. Following the referendum, Montenegro's parliament formally declared independence on 3 June 2006. Subsequently, on 5 June 2006, Serbia's parliament did the same, effectively dissolving the union and marking the final chapter in the disintegration of the former Yugoslavia.
=== Deiodinases === Selenium also plays a role in the functioning of the thyroid gland. It participates as a cofactor for the three thyroid hormone deiodinases. These enzymes activate and then deactivate various thyroid hormones and their metabolites. It may inhibit Hashimoto's disease, an auto-immune disease in which the body's own thyroid cells are attacked by the immune system. A reduction of 21% on TPO antibodies was reported with the dietary intake of 0.2 mg of selenium.
Using the enediol intermediate of the reaction (which allowed solvent protons to enter the reaction from the middle instead of only from the substrate or product) and kinetic isotope effects, he measured the relative free energy of each intermediate and transition state, which allowed him to depict the first free energy profile for an enzyme-catalyzed reaction. This work was done with his long-term collaborator, John Albery. His profile showed that TIM was a "perfect" enzyme in that catalysis is limited only by the rate of diffusion. Later, Knowles applied similar methods to proline racemase, developing an elegant method to discern whether a reaction proceeds via a stepwise or concerted manner and discovering the consequences of "oversaturation", a situation in which the interconversion of unliganded forms of the enzyme limit catalysis. At Harvard, Knowles also did important work on β-lactamases and their mechanism-based inhibitors. And, he provided key insight on the stereochemistry of phosphoryl group transfer reactions, using synthetic phosphoryl groups containing 16O, 17O, and 18O isotopes. Knowles was the author of more than 250 research papers, and advised many doctoral students and post-doctoral researchers at Oxford and at Harvard, including Hagan Bayley, Stephen L. Buchwald, Athel Cornish-Bowden, Andreas Plückthun, and Ronald T. Raines.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.